NaPi2b-targeting exatecan antibody-drug conjugate (ADC Therapeutics)

N/A

Report date: 2025/06/11 11:24:31

Base Information

Drug NameNaPi2b-targeting exatecan antibody-drug conjugate (ADC Therapeutics)

Drug Alias NameNaPi2b targeting ADC (ADC Therapeutics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionSodium-dependent phosphate transport protein 2B modulatorsDNA topoisomerase I inhibitors

TargetsSodium-dependent phosphate transport protein 2BDNA topoisomerase I

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAdc Therapeutics Sa

China Registration ClassN/A

Develop Information

Active CompaniesAdc Therapeutics Sa

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A